Marked Chart Marked Chart Closed

The Marked Chart Wire · Health

GLP-1

China reportedly clears Lilly obesity drug for sale

Regulators in China have reportedly approved Eli Lilly’s oral obesity treatment, positioning the firm ahead of rival Novo Nordisk.

LLY-2.3%

Illustration for the Health desk

The stocks in this story

  1. LLY-2.3%Eli Lilly$1,351

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.

New to this? Read: Reading a stock chart

More Health news

Illustration for the Health desk

Biohaven

Biohaven shares phase 1 results for BHV-1530

Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.